{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T03:37:02Z","timestamp":1775101022983,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72174032"],"award-info":[{"award-number":["72174032"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rare diseases impose a heavy economic burden on patients\u2019 families and society worldwide. This study used the samples from Sichuan Province in China to estimate the curative care expenditure (CCE) of ten rare diseases, for supporting the prioritization of rare disease health policies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Multi-stage cluster sampling method was adopted to investigate 9714 rare disease patients from 1556 medical institutions in Sichuan Province. Based on the System of Health Accounts 2011, this study estimated the total CCE of 10 rare diseases, financing schemes, and their allocation among different medical institutions and groups of people.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In 2018, the total CCE of the ten rare diseases was $19.00 million, the three costliest rare diseases were Hemophilia ($4.38 million), Young-onset Parkinson\u2019s disease ($2.96 million), and Systemic Sclerosis ($2.45 million). Household out-of-pocket expenditure (86.00% for outpatients, 41.60% for inpatients) and social health insurance (7.85% for outpatients; 39.58% for inpatients) were the main sources of financing CCE. The out-of-pocket expenditures for patients with Young-onset Parkinson\u2019s disease, Congenital Scoliosis, and Autoimmune Encephalitis accounted for more than 60% of the total CCE. More than 80% of the rare disease CCE was incurred in general hospitals. The 40\u201359 age group accounted for the highest CCE (38.70%) while men spent slightly more (55.37%) than women (44.64%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>As rare disease treatment is costly and household out-of-pocket expenditure is high, we suggest taking steps to include rare disease drugs in the National Reimbursement Drug List and scientifically re-design insurance coverage. It is also necessary to explore a multi-tiered healthcare security system to pay for the CCE of rare diseases and reduce the economic burden on patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13023-022-02524-1","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T22:02:39Z","timestamp":1665266559000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rare disease curative care expenditure-financing scheme-health provider\u2013beneficiary group analysis: an empirical study in Sichuan Province, China"],"prefix":"10.1186","volume":"17","author":[{"given":"Jia","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0457-9323","authenticated-orcid":false,"given":"Lian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yitong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hailun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"2524_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.12688\/f1000research.4268.1","volume":"4","author":"RJ Arnold","year":"2015","unstructured":"Arnold RJ, Bighash L, Bry\u00f3n Nieto A, Branco T, de Ara\u00fajo G, Gay-Molina JG, Augustovski F. The role of globalization in drug development and access to orphan drugs: orphan drug legislation in the US\/EU and in Latin America. F1000Research. 2015;4:57. https:\/\/doi.org\/10.12688\/f1000research.4268.1.","journal-title":"F1000Research"},{"issue":"1","key":"2524_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5582\/irdr.2012.v1.1.3","volume":"1","author":"P Song","year":"2012","unstructured":"Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: current status and future perspectives. Intractable Rare Dis Res. 2012;1(1):3\u20139. https:\/\/doi.org\/10.5582\/irdr.2012.v1.1.3.","journal-title":"Intractable Rare Dis Res"},{"issue":"9642","key":"2524_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/S0140-6736(08)61393-8","volume":"372","author":"S Hayashi","year":"2008","unstructured":"Hayashi S, Umeda T. 35 years of Japanese policy on rare diseases. Lancet. 2008;372(9642):889\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(08)61393-8.","journal-title":"Lancet"},{"issue":"2","key":"2524_CR4","doi-asserted-by":"publisher","first-page":"145","DOI":"10.5582\/irdr.2018.01056","volume":"7","author":"J He","year":"2018","unstructured":"He J, Kang Q, Hu J, Song P, Jin C. China has officially released its first national list of rare diseases. Intractable Rare Dis Res. 2018;7(2):145\u20137. https:\/\/doi.org\/10.5582\/irdr.2018.01056.","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"2524_CR5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2515\/therapie\/2015021","volume":"70","author":"Y Tillet","year":"2015","unstructured":"Tillet Y, Maillols-Perroy AC. Les m\u00e9dicaments orphelins: des opportunit\u00e9s m\u00e9connues pour les d\u00e9veloppeurs en Europe. Therapies. 2015;70(4):351\u20137. https:\/\/doi.org\/10.2515\/therapie\/2015021 (in French).","journal-title":"Therapies"},{"issue":"2","key":"2524_CR6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S1474-4422(11)70001-1","volume":"10","author":"The Lancet Neurology","year":"2011","unstructured":"The Lancet Neurology. Rare neurological diseases: a united approach is needed. Lancet Neurol. 2011;10(2):109. https:\/\/doi.org\/10.1016\/S1474-4422(11)70001-1.","journal-title":"Lancet Neurol"},{"issue":"2","key":"2524_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1089\/hum.2017.215","volume":"29","author":"S Feng","year":"2018","unstructured":"Feng S, Liu S, Zhu C, Gong M, Zhu Y, Zhang S. National rare diseases registry system of China and related cohort studies: vision and roadmap. Hum Gene Ther. 2018;29(2):128\u201335. https:\/\/doi.org\/10.1089\/hum.2017.215.","journal-title":"Hum Gene Ther"},{"issue":"9","key":"2524_CR8","doi-asserted-by":"publisher","first-page":"A550","DOI":"10.1016\/j.jval.2017.08.859","volume":"20","author":"B Rupasinghe","year":"2017","unstructured":"Rupasinghe B, Gilbane A, Schlegel CR, Walsh K, Degun R. Launching combination therapies in rare diseases: is high cost burden restricting access. Value Health. 2017;20(9):A550. https:\/\/doi.org\/10.1016\/j.jval.2017.08.859.","journal-title":"Value Health"},{"issue":"7","key":"2524_CR9","doi-asserted-by":"publisher","first-page":"A527","DOI":"10.1016\/j.jval.2014.08.1666","volume":"17","author":"E Tasdemir","year":"2014","unstructured":"Tasdemir E, Magestro M, Griner BP, Cummins G, Van EA, Kreeftmeijer J, Niemira J, Tao C. Prevalence-based measurement of the economic burden of rare diseases: case review to determine the annual cost of acromegaly in France. Value Health. 2014;17(7):A527. https:\/\/doi.org\/10.1016\/j.jval.2014.08.1666.","journal-title":"Value Health"},{"issue":"7","key":"2524_CR10","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/bloodadvances.2020003424","volume":"5","author":"TW Buckner","year":"2021","unstructured":"Buckner TW, Bocharova I, Hagan K, Bensimon AG, Yang H, Wu EQ, Sawyer EK, Li N. Health care resource utilization and cost burden of hemophilia B in the United States. Blood Adv. 2021;5(7):1954\u201362. https:\/\/doi.org\/10.1182\/bloodadvances.2020003424.","journal-title":"Blood Adv"},{"key":"2524_CR11","doi-asserted-by":"publisher","first-page":"102162","DOI":"10.1016\/j.msard.2020.102162","volume":"43","author":"M Paz-Zulueta","year":"2020","unstructured":"Paz-Zulueta M, Par\u00e1s-Bravo P, Cantarero-Prieto D, Bl\u00e1zquez-Fern\u00e1ndez C, Oterino-Dur\u00e1n A. A literature review of cost-of-illness studies on the economic burden of multiple sclerosis. Mult Scler Relat Disord. 2020;43:102162. https:\/\/doi.org\/10.1016\/j.msard.2020.102162.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"2524_CR12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1186\/s13023-018-0892-5","volume":"13","author":"ATG Chiu","year":"2018","unstructured":"Chiu ATG, Chung CCY, Wong WHS, Lee SL, Chung BHY. Healthcare burden of rare diseases in Hong Kong\u2014adopting ORPHAcodes in ICD-10 based healthcare administrative datasets. Orphanet J Rare Dis. 2018;13(1):147. https:\/\/doi.org\/10.1186\/s13023-018-0892-5.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"2524_CR13","doi-asserted-by":"publisher","first-page":"e0204206","DOI":"10.1371\/journal.pone.0204206","volume":"13","author":"JC Hsu","year":"2018","unstructured":"Hsu JC, Wu HC, Feng WC, Chou CH, Lai EC, Lu CY. Disease and economic burden for rare diseases in Taiwan: a longitudinal study using Taiwan\u2019s National Health Insurance Research Database. PLoS ONE. 2018;13(9):e0204206. https:\/\/doi.org\/10.1371\/journal.pone.0204206.","journal-title":"PLoS ONE"},{"issue":"1","key":"2524_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13023-019-1168-4","volume":"14","author":"X Cai","year":"2019","unstructured":"Cai X, Yang H, Genchev GZ, Lu H, Yu G. Analysis of economic burden and its associated factors of twenty-three rare diseases in Shanghai. Orphanet J Rare Dis. 2019;14(1):233. https:\/\/doi.org\/10.1186\/s13023-019-1168-4.","journal-title":"Orphanet J Rare Dis"},{"key":"2524_CR15","unstructured":"China Daily. Rare disease medicine debuts in China. http:\/\/www.gov.cn\/xinwen\/2019-03\/02\/content_5369882.htm. Accessed on 28 February 2020."},{"issue":"13","key":"2524_CR16","doi-asserted-by":"publisher","first-page":"5444","DOI":"10.3390\/su12135444","volume":"12","author":"X Yan","year":"2020","unstructured":"Yan X, Dong D, He S, Webster C. Examining trans-provincial diagnosis of rare diseases in China: the importance of healthcare resource distribution and patient mobility. Sustainability. 2020;12(13):5444. https:\/\/doi.org\/10.3390\/su12135444.","journal-title":"Sustainability"},{"issue":"1","key":"2524_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13023-016-0454-7","volume":"11","author":"XX Xin","year":"2016","unstructured":"Xin XX, Guan XD, Shi LW. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China. Orphanet J Rare Dis. 2016;11(1):74. https:\/\/doi.org\/10.1186\/s13023-016-0454-7.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"2524_CR18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.healthpol.2017.04.008","volume":"121","author":"M Mueller","year":"2017","unstructured":"Mueller M, Morgan D. New insights into health financing: first results of the international data collection under the system of health accounts 2011 framework. Health Policy. 2017;121(7):764\u20139. https:\/\/doi.org\/10.1016\/j.healthpol.2017.04.008.","journal-title":"Health Policy"},{"issue":"10187","key":"2524_CR19","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/S0140-6736(19)30841-4","volume":"393","author":"Global Burden of Disease Health Financing Collaborator Network","year":"2019","unstructured":"Global Burden of Disease Health Financing Collaborator Network. Past, present, and future of global health financing: a review of development assistance, government, out-of-pocket, and other private spending on health for 195 countries, 1995\u20132050. Lancet. 2019;393(10187):2233\u201360 (published correction appears in Lancet. 2021 Sep 11;398(10304):956).","journal-title":"Lancet"},{"issue":"12","key":"2524_CR20","doi-asserted-by":"publisher","first-page":"e0208298","DOI":"10.1371\/journal.pone.0208298","volume":"13","author":"P Bahuguna","year":"2018","unstructured":"Bahuguna P, Mukhopadhyay I, Chauhan AS, Rana SK, Selvaraj S, Prinja S. Sub-national health accounts: experience from Punjab state in India. PLoS ONE. 2018;13(12):e0208298.","journal-title":"PLoS ONE"},{"issue":"3","key":"2524_CR21","first-page":"9","volume":"34","author":"T Zhai","year":"2015","unstructured":"Zhai T, Zhang Y, Wan Q, et al. Methodological research on China health expenditure estimation based on SHA 2011. Chin Health Econ. 2015;34(3):9\u201311.","journal-title":"Chin Health Econ"},{"issue":"5S","key":"2524_CR22","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.jadohealth.2020.03.033","volume":"67","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Chai P, Huang X, et al. Financing adolescent health in China: how much, who pays, and where it goes. J Adolesc Health. 2020;67(5S):S38\u201347. https:\/\/doi.org\/10.1016\/j.jadohealth.2020.03.033.","journal-title":"J Adolesc Health"},{"issue":"1","key":"2524_CR23","doi-asserted-by":"publisher","first-page":"e156","DOI":"10.1002\/hpm.2952","volume":"35","author":"X Zhang","year":"2020","unstructured":"Zhang X, Zhang X, Yang S. Total per-visit medical expenses incurred by outpatients with diabetes-evidence from six provinces in eastern China. Int J Health Plan Manag. 2020;35(1):e156\u201366. https:\/\/doi.org\/10.1002\/hpm.2952.","journal-title":"Int J Health Plan Manag"},{"issue":"10","key":"2524_CR24","doi-asserted-by":"publisher","first-page":"e0239844","DOI":"10.1371\/journal.pone.0239844","volume":"15","author":"C Chen","year":"2020","unstructured":"Chen C, Song J, Xu X, Zhou L, Wang Y, Chen H. Analysis of influencing factors of economic burden and medical service utilization of diabetic patients in China. PLoS ONE. 2020;15(10):e0239844. https:\/\/doi.org\/10.1371\/journal.pone.0239844.","journal-title":"PLoS ONE"},{"issue":"5","key":"2524_CR25","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1093\/inthealth\/ihaa092","volume":"13","author":"A Yao","year":"2021","unstructured":"Yao A, Shen X, Chai J, Cheng J, Liu R, Feng R, Wang D. Characteristics and implications of insurance-reimbursed inpatient care for gastric and oesophageal cancers in Anhui China. Int Health. 2021;13(5):446\u201355. https:\/\/doi.org\/10.1093\/inthealth\/ihaa092.","journal-title":"Int Health"},{"key":"2524_CR26","doi-asserted-by":"publisher","first-page":"9268660","DOI":"10.1155\/2021\/9268660","volume":"2021","author":"J Zhang","year":"2021","unstructured":"Zhang J, Sun L. Analysis of influencing factors on hospitalization expenses of patients with breast malignant tumor undergoing surgery: based on the neural network and support vector machine. J Healthc Eng. 2021;2021:9268660. https:\/\/doi.org\/10.1155\/2021\/9268660.","journal-title":"J Healthc Eng"},{"issue":"09","key":"2524_CR27","first-page":"60","volume":"21","author":"Y Wen","year":"2020","unstructured":"Wen Y, Chen L, Pan P, et al. Analysis on the medical cost of inpatients with malignant tumors in Sichuan Province from 2015 to 2018. China Acad J Electron Publ House. 2020;21(09):60\u20133.","journal-title":"China Acad J Electron Publ House"},{"issue":"4","key":"2524_CR28","doi-asserted-by":"publisher","first-page":"314","DOI":"10.5582\/bst.2019.01209","volume":"13","author":"J He","year":"2019","unstructured":"He J, Song P, Kang Q, Zhang X, Hu J, Yang Y, Tang M, Chen D, Hu S, Jin C. Overview on social security system of rare diseases in China. Biosci Trends. 2019;13(4):314\u201323. https:\/\/doi.org\/10.5582\/bst.2019.01209.","journal-title":"Biosci Trends"},{"key":"2524_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13023-016-0392-4","volume":"11","author":"S Gong","year":"2016","unstructured":"Gong S, Wang Y, Pan X, Zhang L, Huang R, Chen X, Hu J, Xu Y, Jin S. The availability and affordability of orphan drugs for rare diseases in China. Orphanet J Rare Dis. 2016;11:20. https:\/\/doi.org\/10.1186\/s13023-016-0392-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"10149","key":"2524_CR30","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/S0140-6736(18)31069-9","volume":"392","author":"L Luzzatto","year":"2018","unstructured":"Luzzatto L, Hyry HI, Schieppati A, Costa E, Simoens S, Schaefer F, Roos JCP, Merlini G, K\u00e4\u00e4ri\u00e4inen H, Garattini S, Hollak CE, Remuzzi G, Second Workshop on Orphan Drugs Participants. Outrageous prices of orphan drugs: a call for collaboration. Lancet. 2018;392(10149):791\u20134. https:\/\/doi.org\/10.1016\/S0140-6736(18)31069-9.","journal-title":"Lancet"},{"issue":"10204","key":"2524_CR31","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/S0140-6736(19)32179-8","volume":"394","author":"S Zhang","year":"2019","unstructured":"Zhang S, Chen L, Zhang Z, Zhao Y. Orphan drug development in China: progress and challenges. Lancet. 2019;394(10204):1127\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(19)32179-8.","journal-title":"Lancet"},{"issue":"3","key":"2524_CR32","first-page":"71","volume":"37","author":"L Fei","year":"2018","unstructured":"Fei L, Jing Z, Ming H. Analysis on the medical insurance policy and medical insurance catalog for rare diseases in China. Chin Health Econ. 2018;37(3):71\u20136.","journal-title":"Chin Health Econ"},{"issue":"10031","key":"2524_CR33","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1016\/S0140-6736(16)30418-4","volume":"387","author":"D Dong","year":"2016","unstructured":"Dong D, Wang Y. Challenges of rare diseases in China. Lancet. 2016;387(10031):1906. https:\/\/doi.org\/10.1016\/S0140-6736(16)30418-4.","journal-title":"Lancet"},{"key":"2524_CR34","unstructured":"The Ministry of Human Resources and Social Security. The Ministry of Human Resources and Social Security issued the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition). 2017. http:\/\/www.mohrss.gov.cn\/SYrlzyhshbzb\/dongtaixinwen\/buneiyaowen\/201702\/t20170223_266787.html."},{"issue":"11","key":"2524_CR35","first-page":"55","volume":"52","author":"P Haoran","year":"2020","unstructured":"Haoran P, Jinglun Y. Integration of China\u2019s basic medical insurance system: theoretical debate, practical progress and future prospects. Acad Monthly. 2020;52(11):55\u201365.","journal-title":"Acad Monthly."},{"key":"2524_CR36","unstructured":"Huang R, Shao W. China rare disease healthcare security city report (2020). CORD. 2020. http:\/\/www.cord.org.cn\/#page1."},{"issue":"3","key":"2524_CR37","doi-asserted-by":"publisher","first-page":"A103","DOI":"10.1016\/j.jval.2015.03.601","volume":"18","author":"R Ma","year":"2015","unstructured":"Ma R, Huang L, Zhao D, Xu L. Commercial health insurance\u2014a new power to push China healthcare reform forward? Value Health. 2015;18(3):A103. https:\/\/doi.org\/10.1016\/j.jval.2015.03.601.","journal-title":"Value Health"},{"issue":"4","key":"2524_CR38","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00108-017-0218-z","volume":"59","author":"T M\u00fcller","year":"2018","unstructured":"M\u00fcller T, Jerrentrup A, Sch\u00e4fer JR. Computerunterst\u00fctzte diagnosefindung bei seltenen erkrankungen. Internist. 2018;59(4):391\u2013400. https:\/\/doi.org\/10.1007\/s00108-017-0218-z.","journal-title":"Internist"},{"issue":"1","key":"2524_CR39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.5582\/irdr.2020.03091","volume":"10","author":"L Gong","year":"2021","unstructured":"Gong L, He Q. Establishing a rare diseases center: experiences from Western China. Intractable Rare Dis Res. 2021;10(1):60\u20131. https:\/\/doi.org\/10.5582\/irdr.2020.03091.","journal-title":"Intractable Rare Dis Res"},{"issue":"Suppl 1","key":"2524_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10198-016-0785-2","volume":"17","author":"M Cavazza","year":"2016","unstructured":"Cavazza M, Armeni P, De Santis M, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, et al. Social\/economic costs and quality of life in patients with hemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):53\u201365. https:\/\/doi.org\/10.1007\/s10198-016-0785-2.","journal-title":"Eur J Health Econ"},{"issue":"Suppl 3","key":"2524_CR41","doi-asserted-by":"publisher","first-page":"s567","DOI":"10.2450\/2014.0042-14s","volume":"12","author":"Y Kodra","year":"2014","unstructured":"Kodra Y, Cavazza M, Schieppati A, De Santis M, Armeni P, Arcieri R, et al. The social burden and quality of life of patients with hemophilia in Italy. Blood Transfus. 2014;12(Suppl 3):s567\u201375. https:\/\/doi.org\/10.2450\/2014.0042-14s.","journal-title":"Blood Transfus"},{"issue":"6","key":"2524_CR42","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/hae.13076","volume":"22","author":"EP Kleijn","year":"2016","unstructured":"Kleijn EP, Mauser-Bunschoten K, Fischer C, Smit H, Holtslag CV. Evidence for and cost-effectiveness of physiotherapy in hemophilia: a Dutch perspective. Hemophilia. 2016;22(6):943\u20138. https:\/\/doi.org\/10.1111\/hae.13076.","journal-title":"Hemophilia"},{"issue":"12","key":"2524_CR43","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.3899\/jrheum.120600","volume":"39","author":"DE Furst","year":"2012","unstructured":"Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T, Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Annual medical costs and healthcare resource use in patients with systemic sclerosis in an insured population. J Rheumatol. 2012;39(12):2303\u20139. https:\/\/doi.org\/10.3899\/jrheum.120600.","journal-title":"J Rheumatol"},{"issue":"3","key":"2524_CR44","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3109\/03009742.2014.976653","volume":"44","author":"K Chevreul","year":"2015","unstructured":"Chevreul K, Brigham KB, Gandr\u00e9 C, Mouthon L, BURQOL-RD Research Network. The economic burden and health-related quality of life associated with systemic sclerosis in France. Scand J Rheumatol. 2015;44(3):238\u201346. https:\/\/doi.org\/10.3109\/03009742.2014.976653.","journal-title":"Scand J Rheumatol"},{"issue":"11","key":"2524_CR45","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.autrev.2017.09.010","volume":"16","author":"A Fischer","year":"2017","unstructured":"Fischer A, Zimovetz E, Ling C, Esser D, Schoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017;16(11):1147\u201354. https:\/\/doi.org\/10.1016\/j.autrev.2017.09.010.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"2524_CR46","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5582\/irdr.2019.01069","volume":"8","author":"R Huang","year":"2019","unstructured":"Huang R, Wei Y, Hu J, et al. The progress of, challenges faced by, and future of rare disease patient organizations in China. Intractable Rare Dis Res. 2019;8(2):158\u201360. https:\/\/doi.org\/10.5582\/irdr.2019.01069.","journal-title":"Intractable Rare Dis Res"},{"issue":"5","key":"2524_CR47","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44\u201368. https:\/\/doi.org\/10.1164\/rccm.201807-1255ST.","journal-title":"Am J Respir Crit Care Med"},{"issue":"Suppl 6","key":"2524_CR48","doi-asserted-by":"publisher","first-page":"S338","DOI":"10.1016\/j.amepre.2011.09.002","volume":"41","author":"JR Baker","year":"2011","unstructured":"Baker JR, Riske B, Voutsis M, Cutter S, Presley R. Insurance, home therapy, and prophylaxis in U.S. youth with severe hemophilia. Am J Prev Med. 2011;41(Suppl 6):S338\u201345. https:\/\/doi.org\/10.1016\/j.amepre.2011.09.002.","journal-title":"Am J Prev Med"},{"issue":"s1","key":"2524_CR49","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.3233\/JPD-202135","volume":"10","author":"B Post","year":"2020","unstructured":"Post B, van den Heuvel L, van Prooije T, van Ruissen X, van de Warrenburg B, Nonnekes J. Young onset Parkinson\u2019s disease: a modern and tailored approach. J Parkinsons Dis. 2020;10(s1):S29\u201336. https:\/\/doi.org\/10.3233\/JPD-202135.","journal-title":"J Parkinsons Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-022-02524-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-022-02524-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T22:10:12Z","timestamp":1665267012000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-022-02524-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2524"],"URL":"https:\/\/doi.org\/10.1186\/s13023-022-02524-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"17 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"373"}}